fda statement bpc-157 BPC 157 Banned: Key Facts on the Latest Decision BPC-157: What the Science Actually
Description
Cobalamin and folate status predicts mental development scores in North Indian children 1218 mo of age
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each Subcutaneous doses are much smaller than oral doses because of injection volume limits and because direct subQ absorption skips the gut
These patients have already been diagnosed with a vitamin deficiency in the first place
But topical peptides
Because neither compound is licensed in the UK, no formal pharmacokinetic or pharmacodynamic interaction studies have been conducted or reviewed by the MHRA
10.1096/fasebj.31.1_supplement.993.3Abstract retrieved fromExperimental Biology 2017 Meeting 68 KrivicA.AnicT.SeiwerthS.HuljevD.SikiricP
